FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Algorae Pharmaceuticals Limited Stock AnalysisComprehensive stock analysis for Algorae Pharmaceuticals Limited (LVCLF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisLVCLF
LVCLF
Algorae Pharmaceuticals Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
LVCLF
Home🔹Stocks🔹Algorae Pharmaceuticals Limited

Algorae Pharmaceuticals Limited

LVCLF•OTC

Algorae Pharmaceuticals Limited

LVCLF•OTC
Market cap
$13.43M
Sentiment

Your view on LVCLF

Mkt Cap
$13.43M
Sentiment
Your view
LVCLF
Algorae Pharmaceuticals Limited
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
LVCLF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Algorae Pharmaceuticals Limited

Industry
Biotechnology
Sector
Healthcare
CEO
David Richard Hainsworth
Headquarters
Tower 2, Melbourne, NSW, AU
Industry
Biotechnology
Sector
Healthcare
CEO
David Richard Hainsworth
Headquarters
Tower 2, Melbourne, NSW, AU
Description

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient for the of treatment for dementia, including Alzheimer's disease; NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient to treat cardiovascular disease, including hypertension. It is also developing AlgaraeOS in partnership with the University of New South Wales, an artificial intelligence platform for biopharmaceutical prediction of both fixed dose combination drug targets and repurposed drug targets agnostic to medical indication. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News